Tracking real-world results of a bleeding disorder drug in kids

This study aims to learn more about how well an already-approved hemophilia A treatment works for children during their regular medical care. Researchers will collect information from about 40 children aged 7 to 12 who are already taking the drug damoctocog alfa pegol to prevent bleeding episodes. The study will track bleeding events and quality of life over two years using health diaries and questionnaires, without changing the children's treatment.